IMMVIRX
Updated 75 days ago
- Age: 5 years
- ID: 52855463/1
Level 2, HMRI Building New Lambton Heights, NSW, 2305, Australia
ImmVirX is a clinical stage oncology company developing novel oncolytic viruses to create powerful cancer immunotherapy combinations... ImmVirX was founded in late 2019 by the team from Viralytics, a clinical-stage ASX-listed oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million. We are developing proprietary bio-selected RNA viruses with the capacity to selectively infect and kill cancer cells while also inducing tumour inflammation and achieving immune cell infiltration - potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.Our viral candidates are intended to increase the anti-tumour activity of current cancer immunotherapies, including immune checkpoint inhibitors, CAR-Ts and other cell therapies, and are targeted against a range of difficult-to-treat cancers, including colorectal, gastric, hepatocellular and ovarian cancer... Our team is based in state-of-the-art R&D facilities at the Hunter..
Also known as: ImmVirX Pty Ltd